𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention

✍ Scribed by Armin Steinmetz

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
122 KB
Volume
24
Category
Article
ISSN
1520-7552

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The blood glucose lowering effects of ex
The blood glucose lowering effects of exercise and glibenclamide in patients with Type 2 diabetes mellitus
✍ Gudat, U.; Bungert, S.; Kemmer, F.; Heinemann, L. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 2 views

Physical exercise is associated with a fall in serum insulin levels, whereas sulphonylurea administration increases insulin release. To date, the opposing effects of exercise and sulphonylurea administration have not been systematically studied in Type 2 diabetic patients, who are not infrequently t

Missense mutations in the TGM2 gene enco
Missense mutations in the TGM2 gene encoding transglutaminase 2 are found in patients with early-onset type 2 diabetes
✍ O. Porzio; O. Massa; V. Cunsolo; C. Colombo; M. Malaponti; F. Bertuzzi; T. Hanse 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 310 KB

Transglutaminase 2 (TG2 or TGM2) is a multi-functional enzyme which catalyzes transamidation reactions or acts as a G-protein in intracellular signalling. Tgm2 -/-Mice lacking TG2 activity are glucose intolerant and show impairment of insulin secretion, suggesting an important physiological role for

Efficacy and safety of the PPARγ partial
Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy
✍ Kim Henriksen; Inger Byrjalsen; Per Qvist; Henning Beck-Nielsen; Gitte Hansen; B 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 357 KB 👁 1 views

## Abstract ## Background Treatment of patients with perioxisome proliferator‐activated receptor‐γ full agonists are associated with weight gain, heart failure, peripheral oedema, and bone loss. However, the safety of partial perioxisome proliferator‐activated receptor‐γ agonists has not been esta